5e5 of anti-GUCY2C CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human GUCY2C, His Tag (Cat. No. GUC-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Immobilized Biotinylated Human GUCY2C, His,Avitag (Cat. No. GUC-H82E9) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Monoclonal Anti-Human GUCY2C Antibody, Human IgG1 with a linear range of 0.2-2 ng/mL (QC tested).
The purity of Biotinylated Human GUCY2C, His,Avitag (Cat. No. GUC-H82E9) is more than 90% and the molecular weight of this protein is around 70-85 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Plecanatide | SP-304; GCRA | Approved | Synergy Pharmaceuticals Inc | Trulance | United States | Constipation; Chronic idiopathic constipation | Salix Pharmaceuticals | 2017-01-19 | Constipation; Irritable Bowel Syndrome; Chronic idiopathic constipation | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| PF-07062119 | PF-07062119 | Pfizer Pharmaceuticals Ltd (China) | Details | ||
| GCC19CART | GCC19CART | Phase 1 Clinical | Innovative Cellular Therapeutics Co Ltd | Rectal Neoplasms; Colorectal Neoplasms | Details |
| IM96 CAR-T cell Therapy | Phase 1 Clinical | Beijing Immunochina Medical Science & Technology Co Ltd | Solid tumours; Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
FLAG
Star Staining
ViruStop
Aneuro
ComboX
ActiveMax
GENPower
ClinMax 
Star Ribbon 
